JP2023535443A5 - - Google Patents
Info
- Publication number
- JP2023535443A5 JP2023535443A5 JP2023504620A JP2023504620A JP2023535443A5 JP 2023535443 A5 JP2023535443 A5 JP 2023535443A5 JP 2023504620 A JP2023504620 A JP 2023504620A JP 2023504620 A JP2023504620 A JP 2023504620A JP 2023535443 A5 JP2023535443 A5 JP 2023535443A5
- Authority
- JP
- Japan
Links
Applications Claiming Priority (7)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202063055721P | 2020-07-23 | 2020-07-23 | |
| US63/055,721 | 2020-07-23 | ||
| US202063069071P | 2020-08-23 | 2020-08-23 | |
| US63/069,071 | 2020-08-23 | ||
| US202163143825P | 2021-01-30 | 2021-01-30 | |
| US63/143,825 | 2021-01-30 | ||
| PCT/US2021/040984 WO2022020105A1 (en) | 2020-07-23 | 2021-07-09 | Anti-transferrin receptor (tfr) antibody and uses thereof |
Publications (4)
| Publication Number | Publication Date |
|---|---|
| JP2023535443A JP2023535443A (ja) | 2023-08-17 |
| JP2023535443A5 true JP2023535443A5 (https=) | 2024-07-17 |
| JPWO2022020105A5 JPWO2022020105A5 (https=) | 2024-07-17 |
| JP7803925B2 JP7803925B2 (ja) | 2026-01-21 |
Family
ID=79729848
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023504620A Active JP7803925B2 (ja) | 2020-07-23 | 2021-07-09 | 抗トランスフェリン受容体（ＴｆＲ）抗体およびその使用 |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US20230256112A1 (https=) |
| EP (1) | EP4185315A4 (https=) |
| JP (1) | JP7803925B2 (https=) |
| KR (1) | KR20230041760A (https=) |
| CN (1) | CN116348138A (https=) |
| AU (1) | AU2021312708A1 (https=) |
| BR (1) | BR112023001005A2 (https=) |
| CA (1) | CA3186727A1 (https=) |
| IL (1) | IL299667A (https=) |
| MX (1) | MX2023000962A (https=) |
| WO (1) | WO2022020105A1 (https=) |
Families Citing this family (24)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US12370264B1 (en) | 2018-08-02 | 2025-07-29 | Dyne Therapeutics, Inc. | Complexes comprising an anti-transferrin receptor antibody linked to an oligonucleotide and method of delivering oligonucleotide to a subject |
| US11911484B2 (en) | 2018-08-02 | 2024-02-27 | Dyne Therapeutics, Inc. | Muscle targeting complexes and uses thereof for treating myotonic dystrophy |
| US12097263B2 (en) | 2018-08-02 | 2024-09-24 | Dyne Therapeutics, Inc. | Muscle targeting complexes and uses thereof for treating myotonic dystrophy |
| EP3829595A4 (en) | 2018-08-02 | 2022-08-24 | Dyne Therapeutics, Inc. | MUSCLE-DIRECTED COMPLEXES AND USES THEREOF IN THE TREATMENT OF DYSTROPHINOPATHIES |
| US11168141B2 (en) | 2018-08-02 | 2021-11-09 | Dyne Therapeutics, Inc. | Muscle targeting complexes and uses thereof for treating dystrophinopathies |
| US12018087B2 (en) | 2018-08-02 | 2024-06-25 | Dyne Therapeutics, Inc. | Muscle-targeting complexes comprising an anti-transferrin receptor antibody linked to an oligonucleotide and methods of delivering oligonucleotide to a subject |
| US20220193250A1 (en) | 2018-08-02 | 2022-06-23 | Dyne Therapeutics, Inc. | Muscle targeting complexes and uses thereof for treating facioscapulohumeral muscular dystrophy |
| KR20230044242A (ko) * | 2020-07-23 | 2023-04-03 | 다인 세라퓨틱스, 인크. | 근육 표적화 복합체 및 디스트로핀병증을 치료하기 위한 그의 용도 |
| WO2022020108A1 (en) * | 2020-07-23 | 2022-01-27 | Dyne Therapeutics, Inc. | Muscle-targeting complexes and uses thereof |
| US11672872B2 (en) | 2021-07-09 | 2023-06-13 | Dyne Therapeutics, Inc. | Anti-transferrin receptor antibody and uses thereof |
| US11638761B2 (en) | 2021-07-09 | 2023-05-02 | Dyne Therapeutics, Inc. | Muscle targeting complexes and uses thereof for treating Facioscapulohumeral muscular dystrophy |
| US11771776B2 (en) | 2021-07-09 | 2023-10-03 | Dyne Therapeutics, Inc. | Muscle targeting complexes and uses thereof for treating dystrophinopathies |
| IL309936A (en) * | 2021-07-09 | 2024-03-01 | Dyne Therapeutics Inc | Muscle targeting complexes and formulations for the treatment of dystrophinopathy |
| US11633498B2 (en) | 2021-07-09 | 2023-04-25 | Dyne Therapeutics, Inc. | Muscle targeting complexes and uses thereof for treating myotonic dystrophy |
| US11969475B2 (en) | 2021-07-09 | 2024-04-30 | Dyne Therapeutics, Inc. | Muscle targeting complexes and uses thereof for treating facioscapulohumeral muscular dystrophy |
| EP4396231A1 (en) | 2021-09-01 | 2024-07-10 | Biogen MA Inc. | Anti-transferrin receptor antibodies and uses thereof |
| US20250339553A1 (en) | 2022-04-15 | 2025-11-06 | Dyne Therapeutics, Inc. | Muscle targeting complexes and formulations for treating myotonic dystrophy |
| IL318625A (en) * | 2022-07-29 | 2025-03-01 | Regeneron Pharma | Compositions and methods for transferrin receptor (TFR)-mediated delivery to brain and muscle |
| US20260015409A1 (en) * | 2022-09-20 | 2026-01-15 | Dana-Farber Cancer Institute, Inc. | Receptor-mediated endocytosis for targeted internalization and degradation of membrane proteins and cargos |
| AU2024299328A1 (en) | 2023-07-21 | 2026-01-22 | Marrow Therapeutics, Inc. | Hematopoietic cell targeting conjugates and related methods |
| WO2025090898A1 (en) * | 2023-10-26 | 2025-05-01 | Biogen Ma Inc. | Anti-transferrin receptor antibodies and uses thereof cross reference to related applications |
| WO2025140522A1 (en) * | 2023-12-29 | 2025-07-03 | Nona Biosciences (Suzhou) Co., Ltd. | Anti-tfr1 antibodies, preparation methods and uses thereof |
| CN119161483B (zh) * | 2024-10-16 | 2026-02-06 | 中国人民解放军军事科学院军事医学研究院 | 人源抗转铁蛋白受体1抗体及其应用 |
| CN119192378B (zh) * | 2024-10-16 | 2025-10-17 | 中国人民解放军军事科学院军事医学研究院 | 一种pH敏感型人源抗转铁蛋白受体1抗体 |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2011130164A2 (en) * | 2010-04-13 | 2011-10-20 | The Regents Of The University Of California | Unconjugated anti-tfr antibodies and compositions thereof for the treatment of cancer |
| WO2014189973A2 (en) * | 2013-05-20 | 2014-11-27 | Genentech, Inc. | Anti-transferrin receptor antibodies and methods of use |
| TWI769982B (zh) | 2015-06-24 | 2022-07-11 | 日商Ｊｃｒ製藥股份有限公司 | 通過血腦障壁之抗人類運鐵蛋白受體抗體 |
| FR3049951A1 (fr) * | 2016-04-12 | 2017-10-13 | Univ Rabelais Francois | Nouvelles constructions peptidiques et leur utilisation dans le traitement de la toxoplasmose |
| AR126019A1 (es) * | 2018-05-30 | 2023-09-06 | Novartis Ag | Anticuerpos frente a entpd2, terapias de combinación y métodos de uso de los anticuerpos y las terapias de combinación |
| CN112930193A (zh) | 2018-08-02 | 2021-06-08 | 达因疗法公司 | 肌肉靶向复合物及其在治疗肌肉萎缩中的用途 |
| WO2020028842A1 (en) | 2018-08-02 | 2020-02-06 | Dyne Therapeutics, Inc. | Muscle targeting complexes and uses thereof for treating hypertrophic cardiomyopathy |
| IL312067B2 (en) * | 2018-12-21 | 2025-08-01 | Avidity Biosciences Inc | Anti-transferrin receptor antibodies and uses thereof |
-
2021
- 2021-07-09 CN CN202180064690.5A patent/CN116348138A/zh active Pending
- 2021-07-09 AU AU2021312708A patent/AU2021312708A1/en active Pending
- 2021-07-09 US US18/017,167 patent/US20230256112A1/en active Pending
- 2021-07-09 CA CA3186727A patent/CA3186727A1/en active Pending
- 2021-07-09 BR BR112023001005A patent/BR112023001005A2/pt unknown
- 2021-07-09 IL IL299667A patent/IL299667A/en unknown
- 2021-07-09 KR KR1020237005829A patent/KR20230041760A/ko active Pending
- 2021-07-09 JP JP2023504620A patent/JP7803925B2/ja active Active
- 2021-07-09 EP EP21846109.3A patent/EP4185315A4/en active Pending
- 2021-07-09 WO PCT/US2021/040984 patent/WO2022020105A1/en not_active Ceased
- 2021-07-09 MX MX2023000962A patent/MX2023000962A/es unknown